145 related articles for article (PubMed ID: 20533894)
1. Neurokinin-1 receptor antagonists: a comprehensive patent survey.
Huang SC; Korlipara VL
Expert Opin Ther Pat; 2010 Aug; 20(8):1019-45. PubMed ID: 20533894
[TBL] [Abstract][Full Text] [Related]
2. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic targets for neurokinin-1 receptor antagonists.
Duffy RA
Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
[TBL] [Abstract][Full Text] [Related]
4. Neurokinin 1 receptor antagonists--current prospects.
Alvaro G; Di Fabio R
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):613-21. PubMed ID: 17786860
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
7. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
8. P2X purinergic receptor ligands: recently patented compounds.
Gunosewoyo H; Kassiou M
Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
[TBL] [Abstract][Full Text] [Related]
9. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
10. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
11. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.
Apfel CC; Malhotra A; Leslie JB
Curr Opin Anaesthesiol; 2008 Aug; 21(4):427-32. PubMed ID: 18660647
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
[TBL] [Abstract][Full Text] [Related]
13. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
[TBL] [Abstract][Full Text] [Related]
15. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
16. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
20. Tachykinin NK2 receptor antagonists. A patent review (2006 - 2010).
Altamura M
Expert Opin Ther Pat; 2012 Jan; 22(1):57-77. PubMed ID: 22149761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
